Virginia M Johnson

US Patent:

53524470, Oct 4, 1994

Filed:

Aug 10, 1992

Appl. No.:

7/925417

Inventors:

Virginia Johnson - College Park MD
Richard J. Youle - Garrett Park MD

Assignee:

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

International Classification:

A61K 3944
A61K 3704
C07K 1702

US Classification:

4241831

Abstract:

A potent and specific immunotoxin is prepared by coupling a binding-site inactivated diphtheria toxin (CRM 107) to a new binding moiety consisting of transferrin or a monoclonal antibody against the human transferrin receptor. These immunotoxins are tumor specific and lack the nonspecific toxicity produced by the binding activity of the native toxin. The immunotoxin is useful in treating primary brain tumors, metastatic tumors to the brain, CSF-borne tumors, leptomeningeal leukemia and leptomeningeal carcinomatosis.

US Patent:

57924589, Aug 11, 1998

Filed:

Oct 17, 1994

Appl. No.:

8/323591

Inventors:

Virginia G. Johnson - College Park MD
Larry Greenfield - Emeryville CA
Richard J. Youle - Garrett Park MD
Walter Laird - Pinole CA

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC
Cetus Corporation - Emeryville CA

International Classification:

C12N 900
A61K 3944
A61K 3816
A61K 39395

US Classification:

4241831

Abstract:

A potent and specific immunotoxin is prepared by coupling an inactivated diphtheria toxin to a binding moiety such as a monoclonal antibody or transferrin. The immunotoxins are specific for human tumors and leukemias and are indistinguishable in cell toxicity from that of the native toxin linked to the binding domain without the toxicity to other cells. The immunotoxin is useful in treating graft versus host disease as well as selectively killing tumor cells, such as medulloblastoma and glioblastoma cells.

US Patent:

52080218, May 4, 1993

Filed:

Jan 25, 1989

Appl. No.:

7/301376

Inventors:

Virginia G. Johnson - College Park MD
Larry Greenfield - Emeryville CA
Richard J. Youle - Garrett Park MD
Walter Laird - Pinole CA

Assignee:

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC
Cetus Corporation - Emeryville CA

International Classification:

A61K 3900
C07K 300

US Classification:

424 8591

Abstract:

A potent and specific immunotoxin is prepared by coupling an inactivated diphteria toxin to a binding moiety such as a monoclonal antibody or transferrin. The immunotoxins are specific for human tumors and leukemias and are indistinguishable in cell toxicity from that of the native toxin linked to the binding domain without the toxicity to other cells. The immunotoxin is useful in treating graft versus host disease as well as selectively killing tumor cells, such as medulloblastoma and glioblastoma cells.

US Patent:

57283834, Mar 17, 1998

Filed:

Jun 13, 1994

Appl. No.:

8/258712

Inventors:

Virginia Johnson - College Park MD
Richard J. Youle - Chevy Chase MD

Assignee:

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

International Classification:

A61K 39395

US Classification:

4241831

Abstract:

Potent and specific immunotoxins are prepared by conjugation of moieties binding to receptors on the surface of tumor cells to a mutant diphtheria toxin having A-chain translocation activity, but lacking membrane-binding activity. The immunotoxins are used to treat primary tumors of neurologic origin, metastatic tumors of small cell lung carcinoma or breast carcinoma origin, leptomeningeal leukemia and leptomeningeal carcinomatosis. The preferred route of administration of the immunotoxin is to a compartment of the body containing cerebrospinal fluid.